Any reference to "GLP-1" reflects the manufacturer's positioning around botanical appetite-signaling support and should not be interpreted as equivalent to prescription GLP-1 receptor agonists
Compounded semaglutide is not FDA approved and may come with risks like dosing errors and contamination
Clinical Effectiveness: SURMOUNT-1 Trial (Tirzepatide 15 mg): Duration: 72 weeks Participants: 2,539 adults with obesity Average Weight Loss: 22.5% of body weight 10 mg Dose: 21.4% weight loss 5 mg Dose: 15.0% weight loss Placebo: 2.4% weight loss 5% Weight Loss: 96% of participants 10% Weight Loss: 89% of participants 15% Weight Loss: 78% of participants 20% Weight Loss: 63% of participants This is the best weight loss result ever achieved with medication in clinical trials
Front Pharmacol 14:1291856 Luongo C, De Stefano MA, Ambrosio R et al (2023) Type 2 deiodinase Thr92Ala polymorphism and aging are associated with a decreased pituitary sensitivity to thyroid hormone
Location: New York, New York Andrew Robert Hart Predicting self-rated health from perceived and actual cardiovascular risk among hypertensive patients
Shipping restrictions We are unable to ship this product to the following states: Alabama, Arkansas, California, Hawaii, Kansas, Michigan, Minnesota, and Mississippi